Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Atware currently manages a patent portfolio focused within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action across its active filing history. This activity is localized within the distinct art units identified in the data, indicating a concentrated examination environment for the firm's current intellectual property assets. Such concentration suggests that the company's immediate legal focus is limited to a specific niche of biological innovation.
The prosecution of this portfolio is handled by the distinct examiners listed, including OGUNTADE, ELIZABETH BISOLA. This individual is identified as the busiest examiner for the company, currently overseeing a busiest examiner pending count of 1. Because the busiest examiner workload matches the total pending office actions for the company, the entirety of the firm's active USPTO engagement is channeled through a single point of contact. For a practitioner, this means that the outcome of the company's current prosecution efforts depends on the requirements of OGUNTADE, ELIZABETH BISOLA.
The presence of the specified examiner and art unit reflects a streamlined prosecution profile. There is no internal data to suggest a need for coordinating across different examiner styles or art unit standards. The strategy for Atware remains focused on resolving the pending office action currently on the docket in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17755487 | ANALYSIS MEDIUM FOR IMMUNOASSY AND METHOD FOR DETECTING ANALYTES IN SUCH A MEDIUM | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17755487 | ANALYSIS MEDIUM FOR IMMUNOASSY AND METHOD FOR DETECTING ANALYTES IN SUCH A MEDIUM | OGUNTADE, ELIZABETH BISOLA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17755487 | ANALYSIS MEDIUM FOR IMMUNOASSY AND METHOD FOR DETECTING ANALYTES IN SUCH A MEDIUM | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtware has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Bisola Oguntade has the most, with 1 of Atware's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
